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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. The majority of cases are sporadic (sALS), while
the most common inherited form is due to C9orf72 mutation (C9ALS). A high burden of inclusion pathology is seen
in glia (including oligodendrocytes) in ALS, especially in C9ALS.Myelin basic protein (MBP) messenger RNA (mRNA)
must be transported to oligodendrocyte processes for myelination, a possible vulnerability for normal function.
TDP43 is found in pathological inclusions in ALS and is a component of mRNA transport granules. Thus, TDP43
aggregation could lead to MBP loss. Additionally, the hexanucleotide expansion of mutant C9ALS binds
hnRNPA2/B1, a protein essential for mRNA transport, causing potential further impairment of hnRNPA2/B1 func-
tion, and thus myelination. Using immunohistochemistry for p62 and TDP43 in human post-mortem tissue, we found
a high burden of glial inclusions in the prefrontal cortex, precentral gyrus, and spinal cord in ALS, which was greater
in C9ALS than in sALS cases. Double staining demonstrated that the majority of these inclusions were in oligoden-
drocytes. Using immunoblotting, we demonstrated reduced MBP protein levels relative to PLP (a myelin component
that relies on protein not mRNA transport) and neurofilament protein (an axonal marker) in the spinal cord. This MBP
loss was disproportionate to the level of PLP and axonal loss, suggesting that impaired mRNA transport may be partly
responsible. Finally, we show that in C9ALS cases, the level of oligodendroglial inclusions correlates inversely with
levels of hnRNPA2/B1 and the number of oligodendrocyte precursor cells. We conclude that there is considerable oli-
godendrocyte pathology in ALS, which at least partially reflects impairment of mRNA transport.
© 2020 The Authors. The Journal of Pathology published by JohnWiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-
onset, degenerative motor neurone disease with an inci-
dence of ~1.5–2 per 100 000 people per year [1,2].
About 95% of cases are sporadic (sALS), while 5% are
familial (fALS) [3]. An increasing number of gene muta-
tions have been associated with ALS, the most frequent
being SOD1, TARDBP, FUS, and C9orf72. The condi-
tion is characterised by both upper and lower motor neu-
rone clinical features [2] and a pathological picture of
upper and lower motor neurone and axon degradation,
often with other, extra motor, brain areas involved. A
subset of residual cells in affected regions accumulate
pathological cytoplasmic inclusions of hyperphosphory-
lated, transactive response DNA-binding protein 43 kDa
(TDP43) that is normally involved in multiple aspects of
RNA processing [4,5]. These inclusions may also be
immunolabelled with antisera for ubiquitin and p62.
While TDP43 is normally present in the nucleus, in cells
with inclusions, the nucleus is depleted of TDP43. This
so-called TDP43 proteinopathy is most commonly con-
sidered in the context of neuronal pathology. However,
it is established that TDP43 inclusions are seen in glia
[4,6], and there is significant interest in an important role
for glia in the pathogenesis of ALS. This has led to study
of the trophic support that glia give to motor neurones
and how this is affected by ALS [4,7,8]. For example,
it has recently been demonstrated that oligodendrocytes
derived fromALS cases can induce motor neurone death
in co-culture [9].
Chromosome 9 open reading frame 72 (C9orf72) is
the most commonly mutated gene in ALS, accounting
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for around 37.6% of fALS cases (C9ALS) [10]. Muta-
tions take the form of an expanded GGGGCC hexanu-
cleotide repeat in intron 1 [11,12]. C9ALS cases show
the classical pathology of motor neurone loss and
TDP43 proteinopathy (with a high burden of glial inclu-
sions). However, in addition, RAN-translated dipeptide
repeats (DPRs) form cytoplasmic and intra-nuclear neu-
ronal inclusions which are negative for TDP43. These
are largely seen in the forebrain and cerebellum [13].
Oligodendrocytes are glia responsible for forming
myelin sheaths, which act as electrical insulators and
support axonal homeostasis [14]. Myelination involves
oligodendrocyte processes wrapping axons with multi-
ple membrane layers. This assembly is triggered by a
phase transition of myelin basic protein (MBP), from a
soluble to a more viscous form [15]. MBP is not trans-
lated in the cell body, where it would cause a fatal com-
paction of the organelle membranes. Instead, MBP
mRNA is silenced and transported to the myelin com-
partment by the RNA transport granule, a complex of
proteins and RNA molecules. For transport to occur,
theMBP mRNA must be appropriately spliced and con-
tain the so-called A2 response element (A2RE) in the 30
UTR. The A2RE binds hnRNPA2/B1, which triggers
the assembly of the mRNA-transport granule. Transla-
tion then occurs in the myelin compartment [16].
There are a number of reasons to suppose that disrup-
tions to this process may be relevant to C9orf72-ALS
and ALS more broadly. Firstly, C9orf72 binds
hnRNPA2/B1 and mediates its shuttling between the
nucleus and cytoplasm [17]. Secondly, TDP43 is a com-
ponent of the transport granule [18]. Therefore, it is pos-
sible that the pathological aggregation of TDP43 could
impair mRNA transport and thus the delivery of MBP
mRNA to the myelin compartment, resulting in impaired
formation. In support of this, it appears that
oligodendrocyte-specific deletion of TDP43 results in
defective myelination in mice [19].
It has long been established that there is myelin loss in
the motor system in ALS [20]. Interest is still current: In
human post-mortem material, a recent analysis using a
combination of methods (magnetic resonance diffusion
and polarised light imaging and immunohistochemistry)
found reduced myelin integrity in the perforant pathway
[21]. A further study found degeneration of oligodendro-
cytes and myelin deficits in the SOD1 mouse model of
ALS and foci of grey matter myelin loss in human
post-mortem motor cortex [22]. Interestingly, radiologi-
cal evidence is emerging to suggest that myelin degrada-
tion may precede axonal changes in neurodegenerative
disease [23]. Traditionally, it has been assumed that at
least some of this is secondary to axonal loss. However,
it remains possible that oligodendrocyte dysfunction
may also be responsible for axonal injury.
Thus, the literature suggests that (1) ALS pathogene-
sis involves glial cells, inclusion pathology is well docu-
mented in oligodendrocytes, and myelination loss is a
feature of ALS; (2) oligodendrocytes are heavily depen-
dent on mRNA transport for their function, due to the
requirement for MBP to be translated in the myelin
compartment as opposed to the cell body, where it is
toxic; (3) TDP43 is a key component of mRNA transport
granules, suggesting that TDP43 pathology may well
disrupt oligodendrocyte mRNA transport and thereby
myelination; and (4) radiological and pathological stud-
ies of animal models and human disease suggest defec-
tive myelination in ALS.
We therefore sought to determine the extent of inclu-
sion pathology in human sALS and C9ALS cases and
to ascertain whether these inclusions involve oligoden-
droglia. We investigated how glial inclusion pathology
levels in different areas were related. Following this,
we assessed myelin integrity. We hypothesised that
(1) there would be substantial glial inclusion pathology
in both C9ALS and sALS cases; (2) this would affect oli-
godendrocytes; and (3) there would be disrupted myelin




Formalin-fixed, paraffin-embedded blocks of precentral
gyrus, middle frontal gyrus, and spinal cord from
84 ALS patients with pathologically confirmed disease
and 21 controls with no CNS pathology were studied.
Of the 84 ALS cases, 66 did not carry any known
ALS-causing mutation, and 18 carried a C9orf72 muta-
tion. Autopsy tissues were donated to the Sheffield Brain
Tissue Bank (SBTB) with the consent of the next of kin
(supplementarymaterial, Table S1). The SBTBManage-
ment Board gave ethical approval for this study under
the provision to act as a Research Tissue Bank as
approved by the Scotland A Research Ethics Committee
(Ref 08/MRE00/103).
Immunohistochemistry
Sections were immunostained using antibodies against
p62, carbonic anhydrase II, pTDP43, hnRNPA2/B1,
poly-AG, poly-PR, poly-AP, poly-GP, poly-GR, and
MAP2+13, an oligodendrocyte precursor cell marker
(see supplementary material, Table S2 and refs 24 and
25 for suppliers and methods).
Double-staining immunohistochemistry was per-
formed by first performing immunohistochemistry for
the oligodendrocyte marker carbonic anhydrase II (see
below) with diaminobenzidene (DAB) as chromogen.
This was followed by immunostaining for p62 with tet-
ramethylrhodamine (Alexa Fluor 555). The DAB-
labelled oligodendrocytes were visualised in brightfield,
while the Alexa Fluor 555-labelled p62 inclusions were
visualised by their fluorescence. The two images were
then combined to assess co-localisation.
Pathological evaluation
In a single section of spinal cord, the total numbers of
p62-positive, pTDP43-positive, and DPR inclusions
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were counted, as well as oligodendrocyte precursor cells
(OPCs), in the ventral horn and the lateral corticospinal
tracts. In the precentral and middle central gyri, inclu-
sions were counted in ten 25× fields and OPCs in
20 25× fields in layer V of the cortex and the underlying
white matter. Counting was performed blind using a
Dialux 22 brightfield microscope (Leitz, Harlow, UK).
Axonal density in the corticospinal tracts was mea-
sured in sections of the cervical spinal cord. For each
case, four images of 1280 × 1024 pixels were taken
from both tracts (two of each side) using a 100× oil
immersion objective. Five stereology-style counting
frames were randomly chosen within each image, count-
ing a total of 20 frames from each patient.
The relative number of nuclei labelled for hnRNPA2/
B1 in the precentral gyrus white matter and the corti-
cospinal tracts was obtained by counting labelled and
unlabelled nuclei in images of these areas taken using a
20× objective.
Post-mortem tissue protein extraction, SDS-PAGE,
and western blotting
Tissue was homogenised in RIPA buffer with protease
inhibitor (Roche, Welwyn Garden City, UK) and 1 mM
4-benzenesulphonyl fluoride hydrochloride and lysed
on ice for 30 min. Extracts were centrifuged at
21 000 × g for 5 min at 4 C, the supernatant was
extracted, and a BCA assay (Thermo Fisher, Loughbor-
ough, UK) used to measure protein levels. Protein was
denatured in 0.125 M Tris–HCl (pH 6.8), 4% sodium
dodecyl sulphate, 20% glycerol, 0.2 M dithiothreitol,
and 0.02% bromophenol blue at 95 C for 10 min. Sam-
ples (40 μg) were separated by SDS-PAGE and proteins
transferred to PVDF membranes. Membranes were
blocked in 5% reconstituted cow’s milk in Tris-buffered
saline with 0.05% Tween 20 for 1 h. Membranes were
incubated with primary antibodies (supplementary mate-
rial, Table S2) at room temperature for 1 h, then with
HRP-conjugated anti-mouse or anti-rabbit secondary
antibodies for 1 h. Membranes were developed using
enhanced chemiluminescence and non-saturated images
acquired using a G:BOX EF machine and Snapgene
software (Syngene, Cambridge, UK). Protein levels
were quantified using GeneTools (Syngene).
Post-mortem tissue RNA extraction, cDNA synthesis,
and quantitative PCR
Blocks were dissected from the precentral gyrus white
matter and spinal corticospinal tracts and subjected to
either Trizol buffer homogenisation or RNA extraction
using the Direct-zol MiniPrep Plus kit (Zymo Research,
Irvine, CA, USA). cDNA was synthesised from RNA
using a SuperScript II Reverse Transcriptase kit
(Thermo Fisher) and quantified by qPCR using prede-
signed 50 nuclease-quencher assays (Integrated DNA
Technologies, Leuven, Belgium) for MBP (MBP-001
isoform: RefSeq NM_002385-2, Hs.PT.58.2684380)
and PLP1 (Hs.PT.58.39005119).
Statistical analyses
Normality was tested using the Shapiro–Wilk test and
homoscedasticity using the Brown–Forsythe Levene-
type test. Stochastic dominance amongst the difference
groups was assessed by a Kruskal–Wallis test followed
by post hocMann–Whitney tests where relevant. Corre-
lations were assessed by the Kendall tau rank correlation
coefficient.
Results
In the forebrain and spinal cord, the burden of glial
inclusion pathology is greater in ALS than in controls
and greater in C9orf72-ALS than in sporadic ALS
Pathological inclusions affect a minority of cells in ALS,
but they are a key pathological feature of disease. We
counted the number of neuronal and glial p62-positive
(p62+) inclusions in spinal cord (ventral horns and corti-
cospinal tracts), precentral gyrus (cortex and white mat-
ter), and middle frontal gyrus (cortex and white matter).
No sex difference was found in the inclusion counts
(p ≥ 0.1506).
The pattern that emerged across the grey and white
matter of all three regions was that there were greater
numbers of p62+ glial inclusions in the ALS cases than
in controls, with greater pathology in C9ALS than in
sALS cases, and these differences were statistically sig-
nificant (Kruskal–Wallis test followed by post hoc
Mann–Whitney FDR < 0.05) (Figure 1; see supplemen-
tary material, Table S3 for statistical analyses and sup-
plementary material, Figure S1 for neuronal inclusion
counts). Furthermore, the variance in the precentral
and middle frontal gyri glial pathology counts was
greater in C9ALS than in the control and sALS
groups.
We next investigated the relationship between glial
pathology levels in adjacent grey and white matter com-
ponents and between levels of neuronal and glial pathol-
ogy within structures (Table 1): (1) Levels of glial
pathology in adjacent grey and white matter compart-
ments correlated for both sALS and C9ALS cases.
(2) There were correlations between the levels of neuro-
nal and glial pathology in the middle frontal and pre-
central gyri in sporadic cases. C9ALS cases showed
fewer correlations. Importantly, correlations between
glial pathology levels in the spinal cord and glial
pathology in the motor cortex were either low or weak.
We conclude that while there is a relationship between
the glial pathology load in adjacent grey and white mat-
ter compartments, the degree of glial pathology in one
structure cannot be inferred from the glial pathology
level in a remote structure, even within the motor
system.
In sALS brains, glial pathology was more widespread
than neuronal pathology: There was glial, but no neuro-
nal, pathology in the grey matter of 22 out of 49 cases in
the precentral gyrus and 25 out of 56 cases in the middle
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frontal gyrus. This was not the case in C9ALS for which
neuronal and glial pathology were present in both brain
regions in every case.
We conclude that glial inclusion pathology is a signif-
icant burden in ALS. Indeed, it is more widespread than
neuronal pathology in sALS brains.
Glial cytoplasmic inclusions are present in
oligodendrocytes
The glial cells with p62+ inclusions had morphology that
was classically that seen in oligodendrocytes, namely
small (approximately 7 μm in diameter) round-to-oval
nuclei with compact chromatin. This was confirmed by
double-staining immunohistochemistry: Inclusions were
demonstrated using p62 and oligodendroglia were
labelled with carbonic anhydrase II in the precentral
gyrus and spinal cord (supplementary material,
Figure S2). Glial cytoplasmic inclusions were present
in the small amount of oligodendrocyte cytoplasm adja-
cent to the nucleus, and often partially or completely
encase the nucleus, as can be seen with single-label
immunohistochemistry. This obscures it, when visualis-
ing the inclusion with DAB. Carbonic anhydrase II was
first identified as an oligodendrocyte marker in rats [26]
and has been used as such in humans by both us [24] and
others [27].
p62+ glial inclusions outnumber pTDP43+ and DPR
inclusions combined in C9ALS
In the precentral gyrus, the C9ALS cases showed signif-
icantly more p62+ pathology than both controls and
sALS cases. We assessed whether these inclusions in
C9ALS cases could be explained by either phosphory-
lated TDP43 or the five possible DPR polypeptides
(poly-AP, poly-GP, poly-GR, poly-AG, and poly-PR)
as immunolabelled and quantified them using the same
protocols as for p62 (Figure 2). The number of glial
DPR inclusions was negligible compared with that of
p62+ inclusions (all p ≤ 0.0313). There was a greater
number of pTDP43+ inclusions than DPR inclusions,
but the burden of this was still lower than that for p62
(p = 0.0247). It thus seemed that the DPR and pTDP+
Figure 1. p62+ glial cytoplasmic inclusion body pathology in the brain and spinal cord. Boxplots demonstrate a significantly greater burden of
p62+ glial inclusions in sALS cases than in controls, and in C9ALS cases than in both controls and sALS in (A) the grey matter ventral horns,
(B) white matter corticospinal tracts, (C, D) precentral gyrus (C, motor cortex; D, underlying white matter), and (E, F) middle frontal gyrus (E,
neocortex; F, underlying white matter). *p < 0.05, **p < 0.01, ***p < 0.001. Panel G shows a p62-labelled neuronal cytoplasmic inclusion.
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burden combined was insufficient to explain the burden
visualised by p62. In the sALS cases, there was no sig-
nificant difference between the numbers of inclusions
detected by pTDP43 and p62 (Figure 2).
The pattern of TDP43+ inclusion pathology reflects
the pattern of p62+ in the motor system
We sought to determine whether the pattern of pTDP43+
glial pathology burden was similar to that seen for p62+
pathology in the motor system. Immunohistochemistry
for pTDP43 was performed on the spinal cord and pre-
central gyrus. Glial inclusions that were positive for this
antibody were counted in the same manner as for p62
immunohistochemistry above.
Kruskal–Wallis tests found significant intergroup dif-
ferences in the spinal cord ventral horns and corticosp-
inal tracts, as well as the precentral gyrus white matter
and cortex (p ≤ 0.02004, Figure 3; supplementary mate-
rial, Table S3 for statistical results). Further post hoc
analysis revealed that the C9ALS group had greater
numbers of pTDP43+ inclusions than controls in the pre-
central gyrus (motor) cortex and white matter, while the
sALS group did not show a significant difference from
controls.
In the spinal cord, there were intergroup differences in
glial pTDP43+ inclusion scores in the ventral horns
(p = 7.84 × 10−5) and the corticospinal tracts
(p = 7.84 × 10−4, Figure 3). Post hoc tests revealed
greater numbers of glial inclusions in both sALS and
C9ALS cases than in controls, in common with the pat-
tern seen for p62. There was no significant difference
between sALS and C9ALS cases in the inclusion
burden.
Myelin pathology in ALS is manifest as a specific
deficit in MBP relative to PLP protein levels in the
corticospinal tract
Having seen the burden of oligodendroglial p62+ and
pTDP43+ inclusion pathology, we predicted that
Table 1 Correlations between neuronal and glial pathology in sporadic and C9orf72-ALS in various regions by the Kendall tau rank
correlation coefficient
Tested variables z value P value Tau value
C9orf72-ALS
SC neuronal versus SC glial VH 1.65 0.0988 0.296
SC neuronal versus SC glial CST* 2.35 0.0190 0.437
SC glial VH versus SC glial CST*** 3.38 7.25 × 10−4 0.628
PCG neuronal versus PCG glial cortex 0.0902 0.928 0.0168
PCG neuronal versus PCG glial WM 0.633 0.527 0.119
PCG glial GM versus PCG glial WM* 2.53 0.0115 0.471
MFG neuronal versus MFG glial cortex** 2.89 0.00389 0.538
MFG neuronal versus MFG glial WM 1.55 0.122 0.293
MFG glial GM versus MFG glial WM** 2.99 0.00276 0.564
Sporadic ALS
SC neuronal versus SC glial VH 1.89 0.0585 0.211
SC neuronal versus SC glial CST 1.89 0.0583 0.215
SC glial GM versus SC glial CST*** 6.06 1.34 × 10−9 0.665
PCG neuronal versus PCG glial cortex*** 4.01 5.96 × 10−5 0.446
PCG neuronal versus PCG glial WM*** 3.57 3.56 × 10−4 0.400
PCG glial GM versus PCG glial WM** 2.71 0.00655 0.282
MFG neuronal versus MFG glial cortex** 3.09 0.00203 0.351
MFG neuronal versus MFG glial WM 0.997 0.319 0.115
MFG glial GM versus MFG glial WM*** 3.87 1.11 × 10−4 0.408
GM, grey matter (cortex or anterior horn); MFG, middle frontal gyrus; PCG, precentral gyrus; SC, spinal cord; WM, white matter (corticospinal tract or white matter in
gyrus beneath cortex). *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2. Relative numbers of inclusions that are positive for p62,
pTDP43, and five species of RAN-translated DPR. (A) The number of
p62+ inclusions vastly outnumber the pTDP43+ and DPR inclusions in
the precentral gyrus in C9ALS cases (**p < 0.01). (B) There is no signif-
icant difference between p62+ and pTDP43+ inclusion counts in sALS
cases. Panel C shows a glial poly-AP DPR cytoplasmic inclusion (arrow)
in the subcortical white matter of a prefrontal gyrus FFPE section.
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oligodendrocytes would also show mRNA transport
defects. As described above, myelin basic protein
(MBP) is transported as mRNA and then translated to
protein. In contrast, proteolipid protein (PLP) is trans-
lated in the oligodendrocyte soma and transported as a
protein to the myelin compartment. Thus, we hypothe-
sised a disproportionate reduction in MBP compared
with PLP protein in ALS corticospinal tract (where
pTDP43 pathology is seen in both C9ALS and sALS
and shows the greatest contrast between control and
ALS groups).
The expression of MBP and PLP protein in the spinal
cord corticospinal tract white matter was assessed using
western blotting (Figure 4A). The proportion of MBP
relative to PLP loss was investigated by normalising
MBP to PLP. There were significant intergroup differ-
ences in the spinal cord corticospinal tracts. Post hoc
tests revealed a significant reduction in the levels of
MBP normalised to PLP in the spinal cord corticospinal
tract in sALS and C9ALS cases compared with controls
(Figure 4B).We found no intergroup differences in post-
mortem delay (p = 0.4317) and no correlation between
MBP levels and post-mortem delay (p ≥ 0.48), and thus
conclude that post-mortem degradation cannot explain
these results. Furthermore, in the corticospinal tracts,
the deficit inMBP in the twoALS groups compared with
controls is not significant when MBP is normalised to
the internal control, beta-tubulin. Similarly, there are
no significant intergroup differences in PLP normalised
to beta-tubulin (supplementary material, Figure S3),
supporting our contention for a reduction in MBP rela-
tive to PLP.
We postulated that the disruption in protein levels of
MBP relative to PLP in the spinal cord may be due to
mRNA transport defects: Other causes of MBP loss
would be more likely to affect both MBP and PLP
equally rather than disproportionately affecting MBP.
Furthermore, the lack of any intergroup differences in
mRNA level implies that the disruption occurred post-
transcriptionally. However, we wished to further investi-
gate the possibility of MBP loss occurring secondary to
axonal loss in the spinal cord corticospinal tract. We rea-
soned that if there were a primary defect in MBP, the
degree of MBP loss would be out of proportion to the
degree of axonal loss. This hypothesis was tested by
western blotting for MBP normalised to phosphorylated
neurofilament (using SMI31 antibody). Intergroup dif-
ferences were shown in the MBP/neurofilament ratio in
the spinal cord corticospinal tracts (p = 0.00971,
Figure 4C). In both C9ALS and sALS cases, this ratio
was reduced to about 25–50% of that found in controls.
Having identified a deficit in MBP relative to PLP
protein in the spinal cord white matter, we set out to
determine if this was reflected in a relative deficit in
MBP relative to PLP mRNA. RT-qPCR analysis of spi-
nal cord corticospinal tract mRNA for MBP normalised
to PLP revealed no intergroup differences (p = 0.484;
Figure 4D).
In contrast to the spinal cord, the precentral gyrus
(where there is much less marked p62+ and pTDP43+
pathology in ALS than in controls) showed no differ-
ences between groups (Figure 4E,F).
hnRNPA2/B1 expression and the number of
oligodendroglial precursor cells correlate negatively
with oligodendroglial pathology in the precentral
gyrus
The selective reduction of MBP relative to both PLP
(another myelin component) and neurofilament
(an axonal marker) in the spinal cord raises the possibil-
ity of defects in RNA transport. Therefore, we examined
the expression of hnRNPA2/B1, a key component of
MBP mRNA transport granules, in the corticospinal
tracts of the spinal cord and in the precentral gyrus white
matter by immunohistochemistry: hnRNPA2/
B1-positive and -negative glial nuclei were counted to
calculate the percentage of glial nuclei that were positive
in these areas.
While there were intergroup differences in the per-
centage of glial cells positive for hnRNPA2/B1 in the
spinal cord corticospinal tracts (p = 0.003;
Figure 3. Glial TDP43 pathology. Glial pTDP43+ inclusions are seen
in the greatest number in C9ALS cases, in intermediate numbers
in sALS cases, and in the lowest numbers in control cases in
(A) the ventral horns and (B) corticospinal tracts of the spinal cord.
In contrast, glial pTDP43+ inclusion pathology was less marked in
(C) the motor cortex and (D) underlying white matter of the precen-
tral gyrus.
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supplementary material, Figure S4A), post hoc analyses
revealed these to be due to a difference between C9ALS
and sALS cases (p = 0.003). There was no significant
difference between C9ALS cases and controls
(p = 0.23), and sALS cases and controls (p = 0.051).
There were no intergroup differences in the precentral
gyrus white matter (p = 0.741; supplementary material,
Figure S4C). Curiously, the variance seen in the
C9ALS group was greater than for the other groups –
the same pattern as that seen for the number of p62+
and pTDP43+ glial inclusions. It was therefore hypothe-
sised that there would be a negative correlation between
the percentage of hnRNPA2/B1-positive glia and the
burden of glial inclusions in the C9ALS cases in this
region. This negative correlation was indeed statistically
significant (p = 0.011; supplementary material,
Figure S4D).
Having shown that glial p62+ inclusion pathology
loads correlate negatively with hnRNPA2/B1 expres-
sion in the white matter of the precentral gyrus in
C9ALS cases, it was hypothesised that there would be
a commensurate alteration in the numbers of oligoden-
drocyte precursor cells (OPCs), potentially manifesting
as a negative correlation between the number of OPCs
and p62+ inclusions in the precentral gyrus. OPCs were
immunostained (supplementary material, Figure S5F)
using the MAP2+13 antibody [28] and counted in the
spinal cord ventral horns and dorsolateral spinal tracts
(Figure S5A,B), the precentral gyrus grey matter (Figure
S5C), and the precentral gyrus white matter (Figure
Figure 4. Myelin integrity in the motor cortex and spinal cord. (A, B) In the spinal cord, where the greatest levels of pTDP43+ inclusions are
seen, immunoblots for myelin components reveal a significant reduction in MBP protein relative to PLP that is most marked in C9ALS cases
and intermediate in sALS cases. (C) This MBP reduction is also evident when considered relative to the axonal marker neurofilament. (D) In the
spinal cord, the reduction in MBP protein relative to PLP is not reflected in reductions inMBPmRNA. (E, F) In the precentral gyrus, where the
pTDP43+ inclusion burden was less marked, immunoblots of white matter did not reveal a loss of MBP relative to PLP protein.
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S5D). As seen with hnRNPA2/B1+ cells, there was a
negative correlation between the number of stained
OPCs and the number of p62+ inclusions in the precen-
tral gyrus white matter (p = 0.04; supplementary mate-
rial, Figure S5E). There were no significant differences
in the number of OPCs between the groups in either
the spinal cord or the precentral gyrus.
Discussion
We present post-mortem findings in sporadic amyo-
trophic lateral sclerosis (sALS) and mutant C9orf72-
related ALS (C9ALS) cases. First, we quantified p62+
cytoplasmic inclusions in the motor system (spinal cord
and precentral gyrus) as well as extra motor tissue (mid-
dle frontal gyrus). Consistent with the previous litera-
ture, we found that in the motor structures of the spinal
cord (ventral horns and corticospinal tracts), there were
greater numbers of glial inclusions in both sALS and
C9ALS cases compared with controls. Similarly, in the
cortex and underlying white matter of the precentral
gyrus (motor strip) and middle frontal gyrus (extra motor
tissue), both ALS groups (sALS and C9ALS) had
greater numbers of glial inclusions than controls. Impor-
tantly, a number of sALS cases had glial but no neuronal
inclusions in these regions. In contrast to the spinal cord
where sALS and C9ALS cases had a similar glial pathol-
ogy load, in the forebrain, the level of pathology was far
greater in C9ALS than in sALS cases and appeared to
have a much greater variance in the C9ALS group. The
excess of glial pathology in C9ALS compared with
sALS is consistent with previous findings [25]. Our first
hypothesis that there is a substantial burden of glial
pathology in ALS is supported. Double-labelling immu-
nohistochemistry established that the majority of these
glial inclusions were in oligodendroglia, supporting our
second hypothesis.
Having established the predominance of oligodendro-
cyte pathology, we aimed to determine the basis for dis-
rupted oligodendrocyte function. To investigate the
possibility of a component of myelin disruption being
caused by mRNA transport deficiency in oligodendro-
cytes in the spinal cord corticospinal tracts, we took
advantage of the contrasting nature in which the myelin
components MBP and PLP are translated and trans-
ported: As noted earlier, MBP is transported as mRNA
and then translated to protein in the myelin compart-
ment. In contrast, PLP is translated to protein in the cell
body and transported to the myelin compartment as pro-
tein. Thus, any defect in mRNA rather than protein trans-
port will disproportionately affect MBP compared with
PLP. Accordingly, this was demonstrated in our immu-
noblot assessment of MBP and PLP protein in sALS
and C9ALS in the spinal cord corticospinal tract, sup-
porting our hypothesis. There was no significant deficit
in MBP in the precentral gyrus, a region with less
marked inclusion pathology. Furthermore, the deficit in
spinal cord MBP protein was not seen in mRNA level
(assessed by RT-qPCR), suggesting that some of the rel-
ative MBP protein deficit is caused by mechanisms that
act after transcription but before translation, again sug-
gestive of mRNA transport disruption. Furthermore,
the MBP loss was out of proportion to the loss of the
axonal marker neurofilament protein, suggesting that
this component myelin pathology was not secondary to
axonal loss. This is not to say that no myelin degradation
is secondary to axonal loss, only that axonal loss cannot
account for the totality of myelin loss and that primary
oligodendrocyte dysfunction is likely to play a part.
Some support for this comes from the observation that
greater levels of p62+ pathology tended to be seen with
lower hnRNPA2/B1 expression in C9ALS.
A limitation of our data on MBP and PLP levels is the
inherent inter-individual variability that is a feature of
human pathology studies. While the statistical methods
employed assess for intergroup differences within the
context of inter-individual rank differences rather than
variances, this finding of relative reductions inMBP pro-
tein in the spinal cord merits replication with a larger
series of cases.
Our data are in agreement with Kang et al, who found
reductions in MBP but not 20,30-cyclic-nucleotide 30-
phosphodiesterase (CNPase, another myelin compo-
nent) in the spinal cords of ALS cases [22]. MBP reduc-
tions have also been demonstrated in the G93A Sod1
transgenic mouse model of ALS [29].
The density of oligodendrocyte precursor cells did not
show significant differences between ALS groups and
controls in our study. This contrasts with a previous find-
ing of increased NG2 immunoreactivity (which high-
lights both OPCs and some monocytes) in the post-
mortem motor cortex of human ALS cases [22]. Dou-
ble-staining immunohistochemistry in ALS cases
appeared to show a population of hypertrophic Iba1−/
NG2+ cells, which were considered to correspond to oli-
godendroglia. This conclusion should be treated with
caution given evidence that somemicroglia are also neg-
ative for Iba1 [30]. Thus, the discrepancy with our study
may be due to the differing antibodies used: MAP2+13
tends to target more mature oligodendrocyte precursor
cells than NG2 and has less cross-reactivity with mono-
cytes [28].
It is also curious that the C9ALS cases had a p62+ load
that was far in excess of the totality of pathology that
could be detected by immunohistochemistry for
pTDP43 and all five species of dipeptide repeat
(DPR). This excessive load of p62+ inclusion pathol-
ogy in the precentral gyrus of C9ALS cases raises the
question of what this antibody is detecting that cannot
be quantified by pTDP43 or DPR immunohistochemis-
try. This is especially true given that the sALS group
showed similar levels of inclusions on both pTDP43
and p62 labelling. A number of possibilities exist: First,
it is possible that there are DPR aggregates that cannot
be detected by the antibodies available to us. Second, it
is possible that these p62+ inclusions may also include
other proteins that have been found to be incorporated
into pathological cellular aggregates in ALS. These
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include RNA-binding motif protein 45 [31], Rho gua-
nine nucleotide exchange factor [32], and opti-
neurin [33].
Axonal metabolism is critically dependent on the pro-
vision of glucose and lactate by oligodendrocytes
[14,34], suggesting that oligodendrocyte function is
important for neuronal survival. It is thus possible that
oligodendroglial dysfunction could contribute to neuro-
nal death. This has been demonstrated in co-culture sys-
tems [9]. Interestingly, recent neuroimaging data
demonstrate that white matter degeneration may precede
neuronal degeneration in C9ALS, to the point that white
matter degeneration may precede symptom onset [35].
In summary, we have observed oligodendrocyte
inclusion pathology in brain regions where neuronal
pathology was not seen, and a loss of the myelin compo-
nent MBP that was proportionately greater than the loss
of the axon component neurofilament. Together, these
observations suggest that oligodendrocyte and myelin
pathology can outstrip neuronal pathology in some
regions and in a manner that suggests a potential deficit
in mRNA transport.
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